Non-Small Cell Lung Cancer Clinical Trials
A listing of Non-Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 12 clinical trials
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
- 0 views
- 19 Feb, 2024
- 1 location
Immunological Profile Changes In Patients with Advanced Non-Small Cell Lung Cancer Undergoing Treatment with Checkpoint Inhibitor Monotherapy
Researchers would like to study how certain biomarkers (signs in your genes that show how well your body responds to a treatment for a disease or condition) change before, during, and after your standard of care treatment for your non-small cell lung cancer (NSCLC). The purpose of this study is …
- 0 views
- 19 Feb, 2024
- 1 location
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
The purpose of this study is to estimate the progression free survival (PFS) of the combination of Carboplatin plus Pemetrexed plus Atezolizumab plus Bevacizumab for patients with stage IV non-squamous NSCLC who are chemotherapy and immunotherapy naive.
- 0 views
- 19 Feb, 2024
- 1 location
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
To qualify, participants must be adults 18 or older and have locally advanced or metastatic NSCLC with EGFR.
- 0 views
- 19 Feb, 2024
- 1 location
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.
- 0 views
- 19 Feb, 2024
- 1 location
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit with a PD-1 or PD-L1 inhibitor.
- 0 views
- 19 Feb, 2024
- 1 location
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
The purpose of this study is to test the good and bad effects of the study drugs called nivolumab and ipilimumab when given after completing chemotherapy and radiation.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase II study of Concurrent Chemoradiation plus Durvalumab (MEDI4736) followed by Surgery followed by Adjuvant Durvalumab (MEDI4736) in medically operable patients with surgically resectable Stage III (N2) Non-Small Cell Lung Cancer
The purpose of this study is to estimate the pathological complete response rate at the time of surgery in patients with stage IIIA (N2) NSCLC treated with concurrent Carboplatin/Paclitaxel/Durvalumab plus radiation therapy followed by surgical resection followed by adjuvant Durvalumab.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK).
- 0 views
- 19 Feb, 2024
- 1 location
- 1
- 2